Abstract
Despite the significant improvements in knowledge, technology and pharmacology obtained in the last few decades, we are not yet ready to provide individualized therapy for critically ill patients with sepsis. Clinicians tend to manage patients according to evidence-based guidelines that are derived from large randomized trials in which single patient characteristics and types of infection are rarely considered. But, as is well known, different types of infection in patients with different characteristics may cause different consequences and may need different treatments.
One of the aspects that remains rather unexplored in clinical practice is the immune response of the patient in the intensive care unit (ICU). On a day-to-day basis in the ICU we are dealing with patients who have a higher susceptibility to nosocomial infections with multidrug-resistant (MDR) bacteria without really understanding the cause. Antibiotic therapy alone in these patients is frequently insufficient, so it is necessary to study an alternative way to make sure that the immune response can actively participate in the elimination of the pathogens [1]. Infection with MDR bacteria frequently occurs in debilitated patients, such as those with shock, surgical complications, prolonged antibiotic therapies and immunosuppressive therapy [2]. The association between MDR infection and immunoparalysis is likely due to a disorder of innate and adaptive immune responses in critically ill patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Venet F, Lukaszewicz AC, Payen D, Hotchkiss R, Monneret G (2013) Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr Opin Immunol 25:477–483
Pop-Vicas A, Opal SM (2014) The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock. Virulence 5:206–212
Hotchkiss RS, Monneret G, Payen D (2013) Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 13:260–268
Boomer JS, Green JM, Hotchkiss RS (2014) The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? Virulence 5:45–56
Meisel C, Schefold JC, Pschowski R et al (2009) Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 180:640–648
Boomer JS, To K, Chang KC et al (2011) Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306:2594–2605
Boomer JS, Shuherk-Shaffer J, Hotchkiss RS, Green JM (2012) A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care 16:R112
Hazeldine J, Hampson P, Lord JM (2014) The impact of trauma on neutrophil function. Injury 45:1824–1833
Karanika S, Karantanos T, Theodoropoulos GE (2013) Immune response after laparoscopic colectomy for cancer: a review. Gastroenterol Rep (Oxf) 1:85–94
Xiu F, Stanojcic M, Diao L, Jeschke MG (2014) Stress hyperglycemia, insulin treatment, and innate immune cells. Int J Endocrinol 2014:486403
Latz E, Xiao TS, Stutz A (2013) Activation and regulation of the inflammasomes. Nat Rev Immunol 13:397–411
Walsh JG, Muruve DA, Power C (2014) Inflammasomes in the CNS. Nat Rev Neurosci 15:84–97
Kepp O, Galluzzi L, Zitvogel L, Kroemer G (2010) Pyroptosis – a cell death modality of its kind? Eur J Immunol 40:627–630
Franchi L, Munoz-Planillo R, Nunez G (2012) Sensing and reacting to microbes through the inflammasomes. Nat Immunol 13:325–332
Franchi L, Kamada N, Nakamura Y et al (2012) NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat Immunol 13:449–456
Broz P, Monack DM (2013) Noncanonical inflammasomes: caspase-11 activation and effector mechanisms. PLoS Pathog 9:e1003144
Zhao Y, Yang J, Shi J et al (2011) The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 477:596–600
Kofoed EM, Vance RE (2011) Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 477:592–595
Shaw PJ, McDermott MF, Kanneganti TD (2011) Inflammasomes and autoimmunity. Trends Mol Med 17:57–64
Choi AJ, Ryter SW (2014) Inflammasomes: molecular regulation and implications for metabolic and cognitive diseases. Mol Cells 37:441–448
Pontillo A, Brandao LA, Guimaraes RL, Segat L, Athanasakis E, Crovella S (2010) A 3′UTR SNP in NLRP3 gene is associated with susceptibility to HIV-1 infection. J Acquir Immune Defic Syndr 54:236–240
Lev-Sagie A, Prus D, Linhares IM, Lavy Y, Ledger WJ, Witkin SS (2009) Polymorphism in a gene coding for the inflammasome component NALP3 and recurrent vulvovaginal candidiasis in women with vulvar vestibulitis syndrome. Am J Obstet Gynecol 200:303e1–303e6
Guo H, Gao J, Taxman DJ, Ting JP, Su L (2014) HIV-1 Infection Induces Interleukin-1beta Production via TLR8 Protein-dependent and NLRP3 Inflammasome Mechanisms in Human Monocytes. J Biol Chem 289:21716–21726
Pontillo A, Silva LT, Oshiro TM, Finazzo C, Crovella S, Duarte AJ (2012) HIV-1 induces NALP3-inflammasome expression and interleukin-1beta secretion in dendritic cells from healthy individuals but not from HIV-positive patients. AIDS 26:11–18
Jankovic D, Ganesan J, Bscheider M et al (2013) The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med 210:1899–1910
Wiersinga WJ, Leopold SJ, Cranendonk DR, van der Poll T (2014) Host innate immune responses to sepsis. Virulence 5:36–44
Papatriantafyllou M (2013) When LPS sneaks into the cell. Nat Rev Immunol 13:772–773
Shankar-Hari M, Spencer J, Sewell WA, Rowan KM, Singer M (2012) Bench-to-bedside review: Immunoglobulin therapy for sepsis – biological plausibility from a critical care perspective. Crit Care 16:206
Arredondo J, Chernyavsky AI, Karaouni A, Grando SA (2005) Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus. Am J Pathol 167:1531–1544
Ehrenstein MR, Notley CA (2010) The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 10:778–786
Adinolfi E, Raffaghello L, Giuliani AL et al (2012) Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res 72:2957–2969
Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:633–652
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Girardis, M., Busani, S., De Biasi, S. (2015). Immune System Dysfunction and Multidrug-resistant Bacteria in Critically Ill Patients: Inflammasones and Future Perspectives. In: Vincent, JL. (eds) Annual Update in Intensive Care and Emergency Medicine 2015. Annual Update in Intensive Care and Emergency Medicine 2015, vol 2015. Springer, Cham. https://doi.org/10.1007/978-3-319-13761-2_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-13761-2_8
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-13760-5
Online ISBN: 978-3-319-13761-2
eBook Packages: MedicineMedicine (R0)